Following results of 2016, Valenta's Ingavirin® tops Russian market of antiviral medications
According to the DSM Group analytical agency’s audit results, Valenta’s drug Ingavirin® became the leader among antiviral medications for flu and ARVI treatment and prophylaxis in total worth of sales in Russian pharmacies in 2016 – compared to 2015, its sales went up by 68 %.
Also in 2016, more than 13 million packs of Ingavirin® were sold – it is the record amount in the brand’s history.
Ingaviring® is one of products with the highest potential in Valenta’s portfolio in immunology and virology. Meant for the treatment of cold and flu, it has antiviral and anti-inflammatory effects, suppressing the replication and preventing the spread of the viruses in patient’s body.
Detailed prescribing information on the drug can be found on Valenta’s official website http://www.valentapharm.com/ingavirin/